[Neurotrophic peptides of сerebrolysin as a basis for anticonvulsant effect of the drug].

Gromova OA, Kalacheva AG, Grishina TR, Bogacheva TE, Demidov VI, Torshin IY

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2016Cited by 1 (Europe PMC)

PMID27070474DOI10.17116/jnevro20161163155-62PepBankPUB-27070474

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

5 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats with thiosemicarbazide-induced seizures, Cerebrolysin reduced seizure severity.
In plain wordsIn rats with thiosemicarbazide-induced seizures, Cerebrolysin reduced seizure severity.
Peptide
Cerebrolysin
Outcome
DecreaseSeizure severity
Study
ratn: not reported in source
Thiosemicarbazide convulsion model
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
2.5 ml/kg · intraperitoneal · 18 daysAs given in this study (rat).
Source sentences
Summary
Cerebrolysin reduces the severity and duration of seizures caused by thiosemicarbazide and increases the survival rate of animals.
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of cerebrolysin were studied on the thiosemicarbazide model of convulsions in 144 male rats.
Summary · context
Cerebrolysin was introduced intraperitoneally in the dose of 2.5 ml/kg of body mass 5 days a week during 18 days.
Report a problemFND-2707047401
02AnimalAnimal study (in vivo)Efficacy outcome
In rats with thiosemicarbazide-induced seizures, Cerebrolysin reduced seizure duration.
In plain wordsIn rats with thiosemicarbazide-induced seizures, Cerebrolysin shortened seizures.
Peptide
Cerebrolysin
Outcome
DecreaseSeizure duration
Study
ratn: not reported in source
Thiosemicarbazide convulsion model
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
2.5 ml/kg · intraperitoneal · 18 daysAs given in this study (rat).
Source sentences
Summary
Cerebrolysin reduces the severity and duration of seizures caused by thiosemicarbazide and increases the survival rate of animals.
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of cerebrolysin were studied on the thiosemicarbazide model of convulsions in 144 male rats.
Summary · context
Cerebrolysin was introduced intraperitoneally in the dose of 2.5 ml/kg of body mass 5 days a week during 18 days.
Report a problemFND-2707047402
03AnimalAnimal study (in vivo)Efficacy outcome
In rats with thiosemicarbazide-induced seizures, Cerebrolysin increased survival.
In plain wordsIn rats with thiosemicarbazide-induced seizures, Cerebrolysin increased survival.
Peptide
Cerebrolysin
Outcome
IncreaseSurvival rate
Study
ratn: not reported in source
Thiosemicarbazide convulsion model
Outcome group
Mortality · Nervous system and cognition
Studied dose
2.5 ml/kg · intraperitoneal · 18 daysAs given in this study (rat).
Source sentences
Summary
Cerebrolysin reduces the severity and duration of seizures caused by thiosemicarbazide and increases the survival rate of animals.
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of cerebrolysin were studied on the thiosemicarbazide model of convulsions in 144 male rats.
Summary · context
Cerebrolysin was introduced intraperitoneally in the dose of 2.5 ml/kg of body mass 5 days a week during 18 days.
Report a problemFND-2707047403
04AnimalAnimal study (in vivo)Efficacy outcome
In rats, Cerebrolysin reduced ischemic neurocyte injury induced by thiosemicarbazide.
In plain wordsIn rats, Cerebrolysin reduced ischemic nerve-cell injury induced by thiosemicarbazide.
Peptide
Cerebrolysin
Outcome
DecreaseIschemic neurocyte injury
Study
ratn: not reported in source
Thiosemicarbazide convulsion model
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
2.5 ml/kg · intraperitoneal · 18 daysAs given in this study (rat).
Source sentences
Summary
Cerebrolysin substantially minimizes the ischemic injury of neurocytes induced by thiosemicarbazide and contributes to the restoration of brain tissue morphology.
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of cerebrolysin were studied on the thiosemicarbazide model of convulsions in 144 male rats.
Summary · context
Cerebrolysin was introduced intraperitoneally in the dose of 2.5 ml/kg of body mass 5 days a week during 18 days.
Report a problemFND-2707047406
05AnimalAnimal study (in vivo)Efficacy outcome
In rats, Cerebrolysin contributed to restoration of brain tissue morphology after thiosemicarbazide injury.
In plain wordsIn rats, Cerebrolysin helped restore brain tissue structure after thiosemicarbazide injury.
Peptide
Cerebrolysin
Outcome
IncreaseBrain tissue morphology restoration
Study
ratn: not reported in source
Thiosemicarbazide convulsion model
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
2.5 ml/kg · intraperitoneal · 18 daysAs given in this study (rat).
Source sentences
Summary
Cerebrolysin substantially minimizes the ischemic injury of neurocytes induced by thiosemicarbazide and contributes to the restoration of brain tissue morphology.
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of cerebrolysin were studied on the thiosemicarbazide model of convulsions in 144 male rats.
Summary · context
Cerebrolysin was introduced intraperitoneally in the dose of 2.5 ml/kg of body mass 5 days a week during 18 days.
Report a problemFND-2707047407

Studies that did not test the peptide alone2

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

06AnimalNot a test of Cerebrolysin aloneAnimal study (in vivo)Efficacy outcome
In the rat seizure model, Cerebrolysin with gabapentin potentiated anticonvulsant action.
In plain wordsIn rats, the Cerebrolysin and gabapentin regimen potentiated anticonvulsant action.
Peptide
Cerebrolysin
Outcome
IncreaseGabapentin anticonvulsant action
Study
ratn: not reported in source
Thiosemicarbazide convulsion model
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
Cerebrolysin potentiates the anticonvulsant action of gabapentin and sodium valproate.
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of cerebrolysin were studied on the thiosemicarbazide model of convulsions in 144 male rats.
Summary · context
Cerebrolysin was introduced intraperitoneally in the dose of 2.5 ml/kg of body mass 5 days a week during 18 days.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-2707047404
07AnimalNot a test of Cerebrolysin aloneAnimal study (in vivo)Efficacy outcome
In the rat seizure model, Cerebrolysin with sodium valproate potentiated anticonvulsant action.
In plain wordsIn rats, the Cerebrolysin and sodium valproate regimen potentiated anticonvulsant action.
Peptide
Cerebrolysin
Outcome
IncreaseSodium valproate anticonvulsant action
Study
ratn: not reported in source
Thiosemicarbazide convulsion model
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
Cerebrolysin potentiates the anticonvulsant action of gabapentin and sodium valproate.
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of cerebrolysin were studied on the thiosemicarbazide model of convulsions in 144 male rats.
Summary · context
Cerebrolysin was introduced intraperitoneally in the dose of 2.5 ml/kg of body mass 5 days a week during 18 days.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-2707047405

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.